GSK (LON:GSK) Stock Rating Reaffirmed by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by stock analysts at Deutsche Bank Aktiengesellschaft in a report released on Tuesday, MarketBeat Ratings reports. They currently have a GBX 1,850 ($24.33) price objective on the stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 11.18% from the company’s current price.

Several other research firms have also commented on GSK. Berenberg Bank reiterated a “buy” rating and issued a GBX 1,820 ($23.93) price target on shares of GSK in a research report on Wednesday, August 14th. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Monday, July 29th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 ($27.61) price objective on shares of GSK in a research report on Thursday, June 27th. Finally, Barclays restated an “equal weight” rating and issued a GBX 1,725 ($22.68) target price on shares of GSK in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of GBX 1,805.71 ($23.74).

GSK Price Performance

GSK stock opened at GBX 1,664 ($21.88) on Tuesday. GSK has a 52 week low of GBX 1,359.60 ($17.88) and a 52 week high of GBX 1,823.50 ($23.98). The firm has a market capitalization of £67.89 billion, a P/E ratio of 1,472.57, a price-to-earnings-growth ratio of 1.47 and a beta of 0.29. The company has a fifty day simple moving average of GBX 1,557.48 and a two-hundred day simple moving average of GBX 1,635.87. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04.

Insiders Place Their Bets

In other news, insider Wendy Becker acquired 446 shares of GSK stock in a transaction on Thursday, June 20th. The shares were bought at an average cost of GBX 1,614 ($21.22) per share, for a total transaction of £7,198.44 ($9,465.40). Insiders have purchased 462 shares of company stock worth $744,868 in the last three months. Corporate insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.